Global OligonucleotideSynthesis Market, by Equipment & Services (Equipment/Synthesizer,Reagents, and Services (Oligo Synthesis, Modification, and Purification)), byTechnology (Column-based, and Microarray-based), by Nucleic Acid (DNA and RNA),by Application (Drug Discovery and Therapeutics), by End User (AcademicResearch Institutes, Diagnostic Laboratories, and Pharmaceutical-BiotechnologyCompanies), and by Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa), is estimated to be valued at US$ 2,874.1 Million in2020 and is expected to exhibit a CAGR of 11.3% during the forecast period(2020-2027), as highlighted in a new report published by Coherent MarketInsights.
Key companies are focusing onlaunching new services such as oligonucleotide synthesis, which is expected todrive growth of the global oligonucleotide synthesis market during the forecastperiod. For instance, in March 2017, Eurofins Genomics launched a DNA synthesisservice based on the company's next-generation synthesis platform in the U.S.The service is designed to provide to supply small quantities of high-qualityoligonucleotides for molecular biology and synthetic biology.
Global Oligonucleotide SynthesisMarket – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus pandemic hasaffected each and every market globally. There has been increasing demand foreffective treatment against COVID-19. Presently, pharmaceutical companies andhealthcare providers are focused on discovering more efficient use ofoligonucleotides and its application to prevent the spread of COVID-19.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/4257
For instance, in 2020, InnovativeGenomic Institute stated that they are working on aerosolized locked nucleicacid modified antisense oligonucleotide that can be inhaled or nebulized forthe treatment of COVID-19 infection. Such innovations are generating aninterest amongst healthcare providers and driving them to fight againstCOVID-19 pandemic. Thus, COVID-19 has affected the global oligonucleotidesynthesis market in a positive way.
Browse 47 Market Data Tables and35 Figures spread through 167 Pages and in-depth TOC on “OligonucleotideSynthesis Market”- Global Forecast to 2027, by Equipment & Services(Equipment/Synthesizer, Reagents, and Services (Oligo Synthesis, Modification,and Purification)), by Technology (Column-based and Microarray-based), byNucleic Acid (DNA and RNA), by Application (Drug Discovery and Therapeutics),by End User (Academic Research Institutes, Diagnostic Laboratories, andPharmaceutical - Biotechnology Companies), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa).
Market players are focusing ondeveloping antisense oligonucleotides for the treatment of various diseasessuch as Duchenne Muscular Dystrophy (DMD), which is expected to boost themarket growth during the forecast period. For instance, in December 2019,Sarepta Therapeutics, Inc. received approval from the U.S. Food and DrugAdministration for VYONDYS 53 (golodirsen), an antisense oligonucleotide fromSarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, indicated forthe treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmedmutation amenable to exon 53 skipping.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/oligonucleotide-synthesis-market-4257
Key Takeaways of the Global OligonucleotideSynthesis Market:
The global oligonucleotidesynthesis market is expected to exhibit a CAGR of 11.3% during the forecastperiod, owing to expansion of manufacturing facilities by market players. Forinstance, in 2018, Corden Pharma GmbH (Germany) expanded its new overseascommercial oligonucleotide active pharmaceutical ingredient manufacturingfacility at CordenPharma Colorado in the U.S., which will help to grow itsnetwork in Europe and the U.S.
Among equipment & services,equipment/synthesizer segment held a dominant position in the globaloligonucleotide synthesis market in 2019, owing to product launches by marketplayers. For instance, in April 2020 Biolytic Lab Performance Inc., amanufacturer of oligo synthesizers and related lab accessories, introduced itsnew oligo synthesizer, Dr. Oligo 768XLc, for throughput nucleic acid synthesis.
Key players operating in theglobal oligonucleotide synthesis market include Thermo Fisher Scientific,Sigma-Aldrich Corporation, GE Healthcare, Integrated DNA Technologies, Inc.,TriLink BioTechnologies, Inc, BioAutomation Corporation, Twist Bioscience,Shanghai SynTheAll Pharmaceutical Co., CUSABIO Technology LLC, SynbioTechnologies, GENEWIZ, Eurofins Scientific, Agilent Technologies, KanekaEurogentec S.A., and LGC, Biosearch Technologies
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/4257
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
